A Phase I Study of Milatuzumab (hLL1) for Prevention of Acute Graft Versus Host Disease Following Reduced-Intensity Conditioning Allogeneic Stem Cell Transplant in Patients With Hematologic Malignancies
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Milatuzumab (Primary) ; Busulfan; Fludarabine; Methotrexate; Tacrolimus
- Indications Graft-versus-host disease
- Focus Adverse reactions
- Sponsors Gilead Sciences
- 21 Sep 2020 Status changed from active, no longer recruiting to discontinued as PIs agreed no safety signals were shown, drug did not appear to lessen the risk of preventing GVHD no further patients would be enrolled.
- 02 Mar 2015 Status changed from recruiting to active, no longer recruiting, according to ClinicalTrials.gov record.
- 15 Feb 2015 Planned End Date changed from 1 Jan 2016 to 1 Jan 2017 as reported by ClinicalTrials.gov.